Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis



The goal of this study was to review relevant randomized controlled trials in order to determine the clinical efficacy of golimumab in the treatment of ankylosing spondylitis (AS).


Using appropriate keywords, we identified relevant studies using PubMed, Cochrane and Embase. Key pertinent sources in the literature were also reviewed, and all articles published through November 2019 were considered for inclusion. For each study, we assessed odds ratios, mean difference and 95% confidence interval to assess and synthesize outcomes.


We included nine studies with 6363 patients. Compared with placebo, golimumab would significant decreased the value of BASFI, BASMI, BASDAI, total back pain, JSEQ; increased the value of SF-36 PCS and SF-36 MCS; increased the incidence of BASDAI50, ASAS20, ASAS40 and ASAS partial remission. Compared with golimumab 50 mg, golimumab 100 mg would significantly decreased the value of BASFI and total back pain; increased the value of SF-36 PCS and SF-36 MCS; but also increased the incidence of SAE.


Golimumab had a definite effect in the treatment of AS. The higher dose would obtain better efficacy but lead to the incidence of SAE.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Data availability

The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.



Ankylosing spondylitis


Odds ratios


Mean difference


Confidence interval


Bath ankylosing spondylitis functional index


Bath ankylosing spondylitis metrology index


Bath ankylosing spondylitis disease activity index


Ankylosing spondylitis disease activity score


Jenkins sleep evaluation questionnaire


Adverse event


Serious adverse event


Food and drug administration


  1. 1.

    Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, Hsia EC (2014) Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxford, England) 53(9):1654–1663.

    CAS  Article  Google Scholar 

  2. 2.

    Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, Hsu B (2012) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 71(5):661–667.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, Han C, Hsu B (2015) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis 74(4):757–761.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Deodhar A, Reveille JD, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC (2018) Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE Study. J Rheumatol 45(3):341–348.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Frampton JE (2017) Golimumab: a review in inflammatory arthritis. BioDrugs: Clin Immunother Biopharm Gene Therapy 31(3):263–274.

    CAS  Article  Google Scholar 

  6. 6.

    Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402–3412.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A (2015) Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 74(3):538–546.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Kruger K, von Hinuber U, Meier F, Tian H, Bohm K, Jugl SM, Borchert K, Meise D, Konig C, Braun S (2018) Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatol Int 38(11):2121–2131.

    Article  PubMed  Google Scholar 

  9. 9.

    Ma H, Sun F, Zhang YM, Zhang H, Zhu J, Deng XH, Zhang JL, Huang F (2017) The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis. Zhonghua nei ke za zhi 56(12):935–939.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Martinez-Cutillas J, Alerany-Pardo C, Borras-Blasco J, Broto-Sumalla A, Burgos-SanJose A, Climent-Bolta C, Escudero-Vilaplana V, Fernandez-Fuente MA, Ferrit-Martin M, Gomez-Germa P, Martinez-Sesmero JM, Mayorga-Perez J, Menchen-Viso B, Merino-Alonso J, Polache-Vengud J, Sanchez-Guerrero A (2015) The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Exp Rev Pharmacoeconomics Outcomes Res 15(5):851–858.

    Article  Google Scholar 

  11. 11.

    Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev.

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewe RBM, van der Heijde D, Ciurea A (2018) TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 77(1):63–69.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Rahbar MH, Lee M, Hessabi M, Tahanan A, Brown MA, Learch TJ, Diekman LA, Weisman MH, Reveille JD (2018) Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort. Contemp Clin Trials Commun 11:127–135.

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, de Vries F (2015) The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis 74(7):1373–1378.

    Article  PubMed  Google Scholar 

  15. 15.

    Tam LS, Shang Q, Kun EW, Lee KL, Yip ML, Li M, Li TK, Zhu TY, Pui MO, Li EK, Yu CM (2014) The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis-a randomized, placebo-controlled pilot trial. Rheumatology (Oxford, England) 53(6):1065–1074.

    CAS  Article  Google Scholar 

  16. 16.

    van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C (2014) The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol 41(6):1095–1103.

    Article  PubMed  Google Scholar 

  17. 17.

    Wang Y, Zheng GQ, Zhang YG, Song K, Song DY, Zhang XS, Wang Z, Lu N, Mao KY (2018) Proposal of a new treatment-oriented classification system for spinal deformity in ankylosing spondylitis. Spine Deform 6(4):366–372.

    Article  PubMed  Google Scholar 

  18. 18.

    Wronski J, Fiedor P (2019) The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: Are TNF inhibitors safer than we thought? J Clin Pharmacol 59(4):445–462.

    CAS  Article  PubMed  Google Scholar 

Download references


Not applicable.


Not applicable yet.

Author information




SAJ, SJ & BSR: Substantial contributions to conception and design. All authors: Data acquisition, data analysis and interpretation. All authors: Drafting the article or critically revising it for important intellectual content. All authors: Final approval of the version to be published. SJ & ZZ: Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Jiandang Shi.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sayed Abdulla, J., Shi, J., Roy, B.S. et al. Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis. Eur Spine J 29, 1813–1822 (2020).

Download citation


  • Golimumab
  • Ankylosing spondylitis
  • Meta-analysis